Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GCK | P35557 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4755922 | 0.82 | RAB9A (0.71) | SMN1; SMN2RAB9ANPC1HPGDHSD17B10 | |
| SCHEMBL8797071 | 0.82 | NPC1 (0.62) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL706414 | 0.82 | RAB9A (0.71) | SMN1; SMN2MAPTGCKRAB9ANPC1 | |
| SCHEMBL6918311 | 0.76 | GRM5 (0.53) | SMN1; SMN2GCKRAB9ANPC1HPGD | |
| SCHEMBL9070875 | 0.74 | GCK (0.56) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL2664747 | 0.74 | RAB9A (0.77) | SMN1; SMN2BRD4MAPTGCKRAB9A | |
| SCHEMBL4756199 | 0.74 | RAB9A (0.62) | SMN1; SMN2BRD4MAPTRAB9ANPC1 | |
| SCHEMBL28801036 | 0.71 | NPC1 (0.72) | SMN1; SMN2MAPTGCKRAB9ANPC1 | |
| SCHEMBL14018616 | 0.71 | RAB9A (0.72) | SMN1; SMN2BRD4MAPTRAB9ANPC1 | |
| SCHEMBL2664728 | 0.71 | GCK (0.60) | SMN1; SMN2BRD4MAPTGCKRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895752-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES L.C. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895752-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES L.C. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-17 | — | — | US | disclosed |
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-17 | — | — | US | disclosed |
| US-8124632-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES, L.C. (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2009035788-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES L.C. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090036467-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | HAVCR2, EIF2AK2, AADAC | SMN1; SMN2 3410/4885BRD4 54/4885MAPT 4288/4885 |
| US-20090036467-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | HAVCR2, EIF2AK2, AADAC | SMN1; SMN2 3410/4885BRD4 54/4885MAPT 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.